Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 3Vulvar Neoplasms 1Vaginal Neoplasms 1Recurrence 1Penile Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

pembrolizumab 23Paclitaxel 14Cyclophosphamide 13Carboplatin 12Specimen Handling 10Magnetic Resonance Spectroscopy 10Biopsy 9fludarabine 8Nivolumab 7Leucovorin 7Gemcitabine 7Fluorouracil 7Doxorubicin 7aldesleukin 6Oxaliplatin 6Cisplatin 6liposomal doxorubicin 5Topotecan 5Taxes 5Irinotecan 5Interleukin-2 5olaparib 4atezolizumab 4Hyperthermic Intraperitoneal Chemotherapy 4Drug Therapy 4seribantumab 3fludarabine phosphate 3durvalumab 3dostarlimab 3dehydroftorafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × MEDI0457 × Gynecologic × Clear all
NCT03439085 2024-07-09

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

M.D. Anderson Cancer Center

Phase 2 Terminated
41 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡